May 18, 2026 07:01AM
May 18, 2026 07:00AM
May 13, 2026 07:00AM
May 13, 2026 07:00AM
Apr 30, 2026 08:31AM
Apr 30, 2026 08:31AM
Mar 26, 2026 09:28AM Can-Fite BioPharma reports net loss widens to $9.83 million in 2025
Mar 26, 2026 09:27AM
Mar 17, 2026 07:47AM
Mar 4, 2026 10:26AM
Mar 4, 2026 10:25AM
Dec 23, 2025 04:46PM
Dec 16, 2025 09:19AM
Nov 26, 2025 07:00AM Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Jul 30, 2025 07:04AM
Jul 30, 2025 07:04AM
Jul 28, 2025 12:24PM
Jul 28, 2025 12:24PM
Apr 14, 2025 02:29PM
Apr 14, 2025 02:28PM
Apr 14, 2025 08:00AM Can-Fite Reports 2024 Financial Results and Clinical Update
Mar 24, 2025 09:00AM
Feb 18, 2025 07:00AM
Feb 10, 2025 07:10AM
Feb 5, 2025 07:00AM
Jan 27, 2025 07:00AM
Nov 4, 2024 07:08AM
Oct 18, 2024 09:11AM Can-Fite BioPharma (CANF): Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Oct 18, 2024 09:06AM
Oct 7, 2024 07:00AM
Sep 16, 2024 07:00AM
Aug 29, 2024 08:15AM
Jul 17, 2024 07:00AM
Nov 21, 2023 01:53PM
Mar 13, 2023 07:00AM Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Dec 28, 2022 07:01AM
Dec 28, 2022 07:00AM
Dec 8, 2022 07:00AM
Nov 25, 2022 07:00AM
Nov 2, 2022 07:15AM
Oct 25, 2022 07:00AM
Oct 13, 2022 07:00AM Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
Sep 12, 2022 07:00AM
Aug 25, 2022 07:00AM
Aug 23, 2022 07:00AM
Aug 22, 2022 07:00AM
Aug 17, 2022 07:26AM
Aug 17, 2022 07:25AM
Jul 11, 2022 07:01AM Can-Fite BioPharma (CANF) to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
Jul 11, 2022 07:00AM

322,971 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All